Prothrombin G20210A and Factor V Leiden Polymorphisms in Stroke

被引:0
作者
Thierry Paluku They-They
Omar Battas
Ilham Slassi
Mohamed Abdou Rafai
Desire Tshala Katumbay
Sellama Nadifi
机构
[1] Medical School,Laboratory of Genetic and Molecular Pathology
[2] Hassan II University,UFR of Clinical Neuroscience and Biological Psychiatry
[3] Medical School,Neurology Department
[4] Hassan II University,Neurology Department
[5] Ibn Rochd Hospital,UFR Clinic of Neurosciences and Laboratory of Genetic and Molecular Pathology
[6] District Hospitals,undefined
[7] Oregon Health & Science University,undefined
[8] Medical School,undefined
[9] Hassan II University,undefined
来源
Journal of Molecular Neuroscience | 2012年 / 46卷
关键词
Leiden; Genetic polymorphism; Prothrombin; Thrombosis; Stroke;
D O I
暂无
中图分类号
学科分类号
摘要
The molecular epidemiology of stroke is critically lacking in the developing world. We explored the relationships between genetics polymorphism and risk for ischemic stroke among the residents of Casablanca, Morocco. Ninety-one stroke patients matched 1:2 for their age, gender, and ethnic background to 182 healthy controls who were genotyped for the prothrombin G20210A mutation and factor V (FV) Leiden and were assessed for conventional risk factors for stroke. No significant association was found between prothrombin gene mutation with stroke (p = .054). Regarding stroke subtypes, significant relationships between patients with a large artery disease subtype of stroke and this mutation was found compared to controls (p = .046). As a genetic risk factor to develop this event, a strong association was observed when adjusted for conventional vascular risk factors (adjusted OR, 4.3; p = .029). No FV Leiden was found. We suggest that prothrombin mutation but not FV Leiden should be considered as a modest genetic risk factor for large artery disease stroke subtype in the Moroccan population.
引用
收藏
页码:210 / 216
页数:6
相关论文
共 104 条
[1]  
Adams HP(1993)Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment Stroke 24 35-41
[2]  
Bendixen BH(1997)Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease Thromb Haemost 78 1430-1433
[3]  
Kappelle LJ(1998)Prevalence of the prothrombin gene variant 20210 G → A among patients with myocardial infarction Cardiovasc Res 37 42-45
[4]  
Arruda V(1994)Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 64-67
[5]  
Annichino-Bizzacchi JM(2004)Laboratory markers in the diagnosis of venous thromboembolism Circulation 109 14-18
[6]  
Gonçalves MS(2004)Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls Arch Neurol 61 1652-1662
[7]  
Arruda VR(1995)Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke Arterioscler Thromb Vasc Biol 15 783-785
[8]  
Siquiera LH(1988)Reconstruction of human evolution: bringing together genetic, archaeological and linguistic data Proc Natl Acad Sci U S A 85 6002-6006
[9]  
Chiaparini LC(1999)The prothrombin 20210A allele and its association with myocardial infarction Thromb Haemost 81 861-864
[10]  
Bertina RM(1998)Reliable genotyping of the G-20210A mutation of coagulation factor II (prothrombin) Clin Chem 44 349-351